2222514-07-8
Chemical Structure
Palopegteriparatide
Synonym(s): Transcon PTH; ACP-014
- CAS No.: 2222514-07-8
- Formula:N/A
- Molecular Weight:N/A
SMILES: [{X}-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (X= O-methylpolyethylene glycol (2 x 20 kDa mPEG)-Aib)]
Biological Activity: Palopegteriparatide (Transcon PTH) is a prodrug of parathyroid hormone PTH 1-34, which can maintain normal and stable calcium concentrations without the need for calcium and active vitamin D replacement. Palopegteriparatide can be used in research on hypoparathyroidism[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Palopegteriparatide | Palopegteriparatide (Transcon PTH) is a prodrug of parathyroid hormone PTH 1-34, which can maintain normal and stable calcium concentrations without the need for calcium and active vitamin D replacement. Palopegteriparatide can be used in research on hypoparathyroidism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Khan AA, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023;38(1):14-25. [Content Brief]
- [2]. Kontogeorgos G. Parathyroid Hormone Hyper-and Hypoparathyroidism Effect of Treatment and Long-term Follow-up Studies[M]. 2024.
Keywords
